{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-116848","form_type":"8-K","ticker":"ALKS","cik":"0001520262","company_name":"Alkermes plc.","filed_at":"2024-10-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.674292+00:00","generated_at":"2026-05-30T10:27:07.699995+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Alkermes Q3 2024: proprietary net sales up 18% YoY to $273M; GAAP EPS $0.56","bullets":["Total revenues $378.1M vs $380.9M YoY; proprietary net sales $273M (+18% YoY).","LYBALVI sales $74.7M (+47%), VIVITROL $113.7M (+14%), ARISTADA $84.7M.","GAAP net income from continuing ops $92.8M, diluted EPS $0.56; non-GAAP net income $121.4M.","Cash & investments $927.8M; repurchased 4.4M shares for $115.6M in Q3; $200M remaining under buyback.","Company reiterates 2024 financial expectations; advancing ALKS 2680 phase 2 studies in narcolepsy."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-116848","json":"https://secwatch.observer/filing/0000950170-24-116848.json","markdown":"https://secwatch.observer/filing/0000950170-24-116848.md","text":"https://secwatch.observer/filing/0000950170-24-116848.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1520262/000095017024116848/0000950170-24-116848-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1520262/000095017024116848/alks-20241024.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T10:27:07.699995+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}